DNA hypermethylation as a predictor of extramural vascular invasion (EMVI) in rectal cancer

Purpose: DNA hypermethylation in gene promoter regions (CpG islands) is emerging as an important pathway in colorectal cancer tumourigenesis. Whilst genetic mutations have been associated with extramural vascular invasion (EMVI) in rectal cancer, no such association has yet been made with epigenetic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer biology & therapy 2018-03, Vol.19 (3), p.214-221
Hauptverfasser: Kokelaar, Rory F., Jones, Huw G., Williamson, Jeremy, Williams, Namor, Griffiths, A. Paul, Beynon, John, Jenkins, Gareth J., Harris, Dean A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 221
container_issue 3
container_start_page 214
container_title Cancer biology & therapy
container_volume 19
creator Kokelaar, Rory F.
Jones, Huw G.
Williamson, Jeremy
Williams, Namor
Griffiths, A. Paul
Beynon, John
Jenkins, Gareth J.
Harris, Dean A.
description Purpose: DNA hypermethylation in gene promoter regions (CpG islands) is emerging as an important pathway in colorectal cancer tumourigenesis. Whilst genetic mutations have been associated with extramural vascular invasion (EMVI) in rectal cancer, no such association has yet been made with epigenetic factors. Methods: 100 consecutive neoadjuvant-naïve patients undergoing curative surgery for rectal were classified according to the presence or absence of EMVI on histopathological examination. DNA was extracted from tumours and subjected to bisulfite conversion and methylation-specific PCR to determine CIMP status (high, intermediate, or low; according to a validated panel of 8 genes). CIMP status was correlated with EMVI status, histopathological, clinical, and demographic variables, in addition to overall (OS) and disease free (DFS) survival. Results: 51 patients were characterised as CIMP-low, 48 CIMP-intermediate, and one patient CIMP-high. EMVI-positivity was associated with CIMP-intermediate epigenotype (p < 0.001). Patients with EMVI-positive tumours were found to have significantly more advanced disease by pT, pN, and pAJCC categorisation (p = 0.002, p < 0.001, and = p < 0.001, respectively). EMVI-positivity was significantly associated with the requirement for adjuvant chemotherapy (p < 0.001), and worse DFS but not OS (p = 0.012 and p = 0.052). Conclusions: Given the association between CIMP-intermediate epigenotype and EMVI-positivity, and the subsequent disadvantage in pathological stage, requirement for adjuvant therapy and worse survival, tumour epigenotyping could potentially play an important role in personalising patients' cancer care. Further work is required to understand the mechanisms that underlie the observed effect, with the hope that they may provide novel opportunities for intervention and inform treatment decisions in rectal cancer.
doi_str_mv 10.1080/15384047.2017.1416933
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_29260978</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1979172507</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-796f6a56690dbf6015579d090c9308864dce2e1470c4794783e844c0ed22d09a3</originalsourceid><addsrcrecordid>eNp9kUtv1DAUhS0EoqXlJ4C8LIsM14_4sUFUpUClApu2GxaW6ziMkRNP7aQw_x5HM61gw8rXut8959oHoVcEVgQUvCUtUxy4XFEgckU4EZqxJ-iQtG3bqFaKp0vNVLNAB-hFKT8BqKRCP0cHVFMBWqpD9P3D11O83m58Hvy03kY7hTRiW7DFm-y74KaUceqx_z1lO8zZRnxvi5ujzTiMtVzwk_MvNxdv6h1n76aKODs6n4_Rs97G4l_uzyN0_fH86uxzc_nt08XZ6WXjuFBTI7XohW2F0NDd9gLqC6TuQIPTDJQSvHOeesIlOC41l4p5xbkD31FaMcuO0Lud7ma-HXylx7prNJscBpu3Jtlg_u2MYW1-pHtTfYAJUgVO9gI53c2-TGYIxfkY7ejTXAzRUhNJW5AVbXeoy6mU7PtHGwJmCcY8BGOWYMw-mDr3-u8dH6cekqjA-x0Qxj7lwf5KOXZmstuYcp_rf4Zi2P89_gACXZ0r</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1979172507</pqid></control><display><type>article</type><title>DNA hypermethylation as a predictor of extramural vascular invasion (EMVI) in rectal cancer</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Kokelaar, Rory F. ; Jones, Huw G. ; Williamson, Jeremy ; Williams, Namor ; Griffiths, A. Paul ; Beynon, John ; Jenkins, Gareth J. ; Harris, Dean A.</creator><creatorcontrib>Kokelaar, Rory F. ; Jones, Huw G. ; Williamson, Jeremy ; Williams, Namor ; Griffiths, A. Paul ; Beynon, John ; Jenkins, Gareth J. ; Harris, Dean A.</creatorcontrib><description>Purpose: DNA hypermethylation in gene promoter regions (CpG islands) is emerging as an important pathway in colorectal cancer tumourigenesis. Whilst genetic mutations have been associated with extramural vascular invasion (EMVI) in rectal cancer, no such association has yet been made with epigenetic factors. Methods: 100 consecutive neoadjuvant-naïve patients undergoing curative surgery for rectal were classified according to the presence or absence of EMVI on histopathological examination. DNA was extracted from tumours and subjected to bisulfite conversion and methylation-specific PCR to determine CIMP status (high, intermediate, or low; according to a validated panel of 8 genes). CIMP status was correlated with EMVI status, histopathological, clinical, and demographic variables, in addition to overall (OS) and disease free (DFS) survival. Results: 51 patients were characterised as CIMP-low, 48 CIMP-intermediate, and one patient CIMP-high. EMVI-positivity was associated with CIMP-intermediate epigenotype (p &lt; 0.001). Patients with EMVI-positive tumours were found to have significantly more advanced disease by pT, pN, and pAJCC categorisation (p = 0.002, p &lt; 0.001, and = p &lt; 0.001, respectively). EMVI-positivity was significantly associated with the requirement for adjuvant chemotherapy (p &lt; 0.001), and worse DFS but not OS (p = 0.012 and p = 0.052). Conclusions: Given the association between CIMP-intermediate epigenotype and EMVI-positivity, and the subsequent disadvantage in pathological stage, requirement for adjuvant therapy and worse survival, tumour epigenotyping could potentially play an important role in personalising patients' cancer care. Further work is required to understand the mechanisms that underlie the observed effect, with the hope that they may provide novel opportunities for intervention and inform treatment decisions in rectal cancer.</description><identifier>ISSN: 1538-4047</identifier><identifier>EISSN: 1555-8576</identifier><identifier>DOI: 10.1080/15384047.2017.1416933</identifier><identifier>PMID: 29260978</identifier><language>eng</language><publisher>United States: Taylor &amp; Francis</publisher><subject>CIMP ; Epigenetics ; Original ; Rectal Cancer ; Vascular Invasion</subject><ispartof>Cancer biology &amp; therapy, 2018-03, Vol.19 (3), p.214-221</ispartof><rights>2018 Taylor &amp; Francis Group, LLC 2018</rights><rights>2018 Taylor &amp; Francis Group, LLC 2018 Taylor &amp; Francis Group, LLC</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-796f6a56690dbf6015579d090c9308864dce2e1470c4794783e844c0ed22d09a3</citedby><cites>FETCH-LOGICAL-c468t-796f6a56690dbf6015579d090c9308864dce2e1470c4794783e844c0ed22d09a3</cites><orcidid>0000-0002-1076-7294</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790361/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790361/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29260978$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kokelaar, Rory F.</creatorcontrib><creatorcontrib>Jones, Huw G.</creatorcontrib><creatorcontrib>Williamson, Jeremy</creatorcontrib><creatorcontrib>Williams, Namor</creatorcontrib><creatorcontrib>Griffiths, A. Paul</creatorcontrib><creatorcontrib>Beynon, John</creatorcontrib><creatorcontrib>Jenkins, Gareth J.</creatorcontrib><creatorcontrib>Harris, Dean A.</creatorcontrib><title>DNA hypermethylation as a predictor of extramural vascular invasion (EMVI) in rectal cancer</title><title>Cancer biology &amp; therapy</title><addtitle>Cancer Biol Ther</addtitle><description>Purpose: DNA hypermethylation in gene promoter regions (CpG islands) is emerging as an important pathway in colorectal cancer tumourigenesis. Whilst genetic mutations have been associated with extramural vascular invasion (EMVI) in rectal cancer, no such association has yet been made with epigenetic factors. Methods: 100 consecutive neoadjuvant-naïve patients undergoing curative surgery for rectal were classified according to the presence or absence of EMVI on histopathological examination. DNA was extracted from tumours and subjected to bisulfite conversion and methylation-specific PCR to determine CIMP status (high, intermediate, or low; according to a validated panel of 8 genes). CIMP status was correlated with EMVI status, histopathological, clinical, and demographic variables, in addition to overall (OS) and disease free (DFS) survival. Results: 51 patients were characterised as CIMP-low, 48 CIMP-intermediate, and one patient CIMP-high. EMVI-positivity was associated with CIMP-intermediate epigenotype (p &lt; 0.001). Patients with EMVI-positive tumours were found to have significantly more advanced disease by pT, pN, and pAJCC categorisation (p = 0.002, p &lt; 0.001, and = p &lt; 0.001, respectively). EMVI-positivity was significantly associated with the requirement for adjuvant chemotherapy (p &lt; 0.001), and worse DFS but not OS (p = 0.012 and p = 0.052). Conclusions: Given the association between CIMP-intermediate epigenotype and EMVI-positivity, and the subsequent disadvantage in pathological stage, requirement for adjuvant therapy and worse survival, tumour epigenotyping could potentially play an important role in personalising patients' cancer care. Further work is required to understand the mechanisms that underlie the observed effect, with the hope that they may provide novel opportunities for intervention and inform treatment decisions in rectal cancer.</description><subject>CIMP</subject><subject>Epigenetics</subject><subject>Original</subject><subject>Rectal Cancer</subject><subject>Vascular Invasion</subject><issn>1538-4047</issn><issn>1555-8576</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kUtv1DAUhS0EoqXlJ4C8LIsM14_4sUFUpUClApu2GxaW6ziMkRNP7aQw_x5HM61gw8rXut8959oHoVcEVgQUvCUtUxy4XFEgckU4EZqxJ-iQtG3bqFaKp0vNVLNAB-hFKT8BqKRCP0cHVFMBWqpD9P3D11O83m58Hvy03kY7hTRiW7DFm-y74KaUceqx_z1lO8zZRnxvi5ujzTiMtVzwk_MvNxdv6h1n76aKODs6n4_Rs97G4l_uzyN0_fH86uxzc_nt08XZ6WXjuFBTI7XohW2F0NDd9gLqC6TuQIPTDJQSvHOeesIlOC41l4p5xbkD31FaMcuO0Lud7ma-HXylx7prNJscBpu3Jtlg_u2MYW1-pHtTfYAJUgVO9gI53c2-TGYIxfkY7ejTXAzRUhNJW5AVbXeoy6mU7PtHGwJmCcY8BGOWYMw-mDr3-u8dH6cekqjA-x0Qxj7lwf5KOXZmstuYcp_rf4Zi2P89_gACXZ0r</recordid><startdate>20180304</startdate><enddate>20180304</enddate><creator>Kokelaar, Rory F.</creator><creator>Jones, Huw G.</creator><creator>Williamson, Jeremy</creator><creator>Williams, Namor</creator><creator>Griffiths, A. Paul</creator><creator>Beynon, John</creator><creator>Jenkins, Gareth J.</creator><creator>Harris, Dean A.</creator><general>Taylor &amp; Francis</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1076-7294</orcidid></search><sort><creationdate>20180304</creationdate><title>DNA hypermethylation as a predictor of extramural vascular invasion (EMVI) in rectal cancer</title><author>Kokelaar, Rory F. ; Jones, Huw G. ; Williamson, Jeremy ; Williams, Namor ; Griffiths, A. Paul ; Beynon, John ; Jenkins, Gareth J. ; Harris, Dean A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-796f6a56690dbf6015579d090c9308864dce2e1470c4794783e844c0ed22d09a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>CIMP</topic><topic>Epigenetics</topic><topic>Original</topic><topic>Rectal Cancer</topic><topic>Vascular Invasion</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kokelaar, Rory F.</creatorcontrib><creatorcontrib>Jones, Huw G.</creatorcontrib><creatorcontrib>Williamson, Jeremy</creatorcontrib><creatorcontrib>Williams, Namor</creatorcontrib><creatorcontrib>Griffiths, A. Paul</creatorcontrib><creatorcontrib>Beynon, John</creatorcontrib><creatorcontrib>Jenkins, Gareth J.</creatorcontrib><creatorcontrib>Harris, Dean A.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer biology &amp; therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kokelaar, Rory F.</au><au>Jones, Huw G.</au><au>Williamson, Jeremy</au><au>Williams, Namor</au><au>Griffiths, A. Paul</au><au>Beynon, John</au><au>Jenkins, Gareth J.</au><au>Harris, Dean A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>DNA hypermethylation as a predictor of extramural vascular invasion (EMVI) in rectal cancer</atitle><jtitle>Cancer biology &amp; therapy</jtitle><addtitle>Cancer Biol Ther</addtitle><date>2018-03-04</date><risdate>2018</risdate><volume>19</volume><issue>3</issue><spage>214</spage><epage>221</epage><pages>214-221</pages><issn>1538-4047</issn><eissn>1555-8576</eissn><abstract>Purpose: DNA hypermethylation in gene promoter regions (CpG islands) is emerging as an important pathway in colorectal cancer tumourigenesis. Whilst genetic mutations have been associated with extramural vascular invasion (EMVI) in rectal cancer, no such association has yet been made with epigenetic factors. Methods: 100 consecutive neoadjuvant-naïve patients undergoing curative surgery for rectal were classified according to the presence or absence of EMVI on histopathological examination. DNA was extracted from tumours and subjected to bisulfite conversion and methylation-specific PCR to determine CIMP status (high, intermediate, or low; according to a validated panel of 8 genes). CIMP status was correlated with EMVI status, histopathological, clinical, and demographic variables, in addition to overall (OS) and disease free (DFS) survival. Results: 51 patients were characterised as CIMP-low, 48 CIMP-intermediate, and one patient CIMP-high. EMVI-positivity was associated with CIMP-intermediate epigenotype (p &lt; 0.001). Patients with EMVI-positive tumours were found to have significantly more advanced disease by pT, pN, and pAJCC categorisation (p = 0.002, p &lt; 0.001, and = p &lt; 0.001, respectively). EMVI-positivity was significantly associated with the requirement for adjuvant chemotherapy (p &lt; 0.001), and worse DFS but not OS (p = 0.012 and p = 0.052). Conclusions: Given the association between CIMP-intermediate epigenotype and EMVI-positivity, and the subsequent disadvantage in pathological stage, requirement for adjuvant therapy and worse survival, tumour epigenotyping could potentially play an important role in personalising patients' cancer care. Further work is required to understand the mechanisms that underlie the observed effect, with the hope that they may provide novel opportunities for intervention and inform treatment decisions in rectal cancer.</abstract><cop>United States</cop><pub>Taylor &amp; Francis</pub><pmid>29260978</pmid><doi>10.1080/15384047.2017.1416933</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-1076-7294</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1538-4047
ispartof Cancer biology & therapy, 2018-03, Vol.19 (3), p.214-221
issn 1538-4047
1555-8576
language eng
recordid cdi_pubmed_primary_29260978
source EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
subjects CIMP
Epigenetics
Original
Rectal Cancer
Vascular Invasion
title DNA hypermethylation as a predictor of extramural vascular invasion (EMVI) in rectal cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T18%3A48%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=DNA%20hypermethylation%20as%20a%20predictor%20of%20extramural%20vascular%20invasion%20(EMVI)%20in%20rectal%20cancer&rft.jtitle=Cancer%20biology%20&%20therapy&rft.au=Kokelaar,%20Rory%20F.&rft.date=2018-03-04&rft.volume=19&rft.issue=3&rft.spage=214&rft.epage=221&rft.pages=214-221&rft.issn=1538-4047&rft.eissn=1555-8576&rft_id=info:doi/10.1080/15384047.2017.1416933&rft_dat=%3Cproquest_pubme%3E1979172507%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1979172507&rft_id=info:pmid/29260978&rfr_iscdi=true